Johnson & Johnson
JNJ Healthcare Drug Manufacturers General
Johnson & Johnson’s revenue for fiscal 2025 (year ended December 2025) was $94.2 billion, up 6.05% from fiscal 2024. In the quarter to September 2026, revenue grew 5.86%, EPS was flat, free cash flow grew 154.8% and total debt fell 4.82%, each against the same quarter a year earlier. Member of the S&P 500 and Dow Jones; dividend growth for twenty-five consecutive years, revenue growth for three, operating cash flow growth for three; insiders bought in the last twelve months.
Follow JNJ
Johnson & Johnson (JNJ) Free cash flow
Johnson & Johnson's free cash flow for fiscal 2025 was $20.4B, unchanged from fiscal 2024. Over the twelve months to 30 June 2026 it was $22.7B. Over the past ten years it has ranged from $16.8B (fiscal 2016) to $23.2B (fiscal 2019); the current reading is higher than 55% of that period. Johnson & Johnson ranks 1st of 21 Drug Manufacturers General companies by free cash flow.
Free cash flow, annual
Embed this chart
Annual newest first
| Period | Free cash flow | Change |
|---|---|---|
| FY2025 | $20.4B | (0.48%) |
| FY2024 | $20.5B | 10.27% |
| FY2023 | $18.6B | 4.95% |
| FY2022 | $17.7B | (13.39%) |
| FY2021 | $20.5B | (0.12%) |
| FY2020 | $20.5B | (11.60%) |
| FY2019 | $23.2B | 6.67% |
| FY2018 | $21.7B | 10.84% |
| FY2017 | $19.6B | 16.66% |
| FY2016 | $16.8B | (14.11%) |
Quarterly newest first
| Period | Free cash flow | Change |
|---|---|---|
| Jun 2026 | $7.4B | 392.50% |
| Mar 2026 | $1.5B | (74.17%) |
| Dec 2025 | $5.8B | (28.49%) |
| Sep 2025 | $8.1B | 180.06% |
| 42 more quarters | Free account |
Against its own ten years
Free cash flow against peers
| Company | Free cash flow |
|---|---|
| JNJ Johnson & Johnson | $22.7B |
| ABBV AbbVie Inc. compare | $18.2B |
| LLY Eli Lilly and Company compare | $18.2B |
| MRK Merck & Co., Inc. compare | $16.1B |
| NVS Novartis AG compare | $15.2B |
| GILD Gilead Sciences, Inc. compare | $12.9B |
| PFE Pfizer Inc. compare | $11.0B |
| AMGN Amgen Inc. compare | $10.2B |
| AZN AstraZeneca PLC compare | $6.3B |
What Free cash flow is
Free Cash Flow tells an investor how much cash a company’s operations generate after paying for its investment in physical and intangible assets.
Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)
More on JNJ
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement